Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma
- 1 July 2017
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 109, 45-51
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Personalized Treatment of Early-Stage Non-Small-Cell Lung Cancer: The Challenging Role of EGFR InhibitorsFuture Oncology, 2015
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsThe Lancet Oncology, 2015
- Comprehensive molecular profiling of lung adenocarcinomaNature, 2014
- Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsiveExpert Review of Respiratory Medicine, 2011
- Impact of KRAS and EGFR Gene Mutations on Recurrence and Survival in Patients with Surgically Resected Lung AdenocarcinomasAnnals of Surgical Oncology, 2011
- Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung AdenocarcinomaJournal of Thoracic Oncology, 2009
- Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative RecurrenceJournal of Clinical Oncology, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004